Biolinq secures $100M in Series C funding for its intradermal glucose sensor to improve metabolic health in type 2 diabetes, led by Alpha Wave Ventures.
Biolinq secures $100M in Series C funding for its intradermal glucose sensor to improve metabolic health in type 2 diabetes, led by Alpha Wave Ventures.
04/22/25, 4:01 PM
Location
san diegoMoney raised
$100 million
Industry
medical device
health care
biotechnology
Investors
Aphelion Capital, Features Capital, Taisho Pharmaceutical, Hikma Ventures, River Vest Venture Partners, Life Sci Venture Partners, M Ventures, Axa Im Alts, Alpha Wave Ventures
Biolinq announced the successful completion of a $100 million Series C funding round to advance its wearable biosensor technology for type 2 diabetes. Alpha Wave Ventures led the round with support from various existing investors. The funding will help Biolinq pursue regulatory approval and enhance its commercial readiness efforts. The company's glucose sensor is still under investigation and not yet approved by the FDA.
Company Info
Location
10260 sorrento valley road
san diego, california, united states
Additional Info
Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company’s biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous small molecule biosensing.